Please login to the form below

Not currently logged in

Life science execs concerned about UK's competitiveness

Value-based pricing, NHS reforms and the cost of research highlighted as key issues in survey

Reforms to the UK's pricing and healthcare systems, employment issues and the cost of carrying out research in the country are the most pressing issues for life science executives, according to a new survey.

The message from the 2011 UK Life Sciences Leaders Survey was that the industry wants stronger support from the government, particularly when it comes to the country's position as a centre for global pharma R&D.

The survey, which was sponsored by life sciences search consultancy RSA, questioned 249 senior executives from the global life sciences sector and was supported by a number of UK industry groups including the ABPI and the BIA.

Stephen Whitehead, CEO of the Association of British Pharmaceutical Industry (ABPI), said: “The survey indicates that we need to do more to support biopharmaceutical companies and the NHS in creating an environment where innovation, in all its forms, can be allowed to thrive.

“There is much that the government has done to support the industry, particularly through the Growth Review and the Office for Life Sciences. But we need to build on this as part of a continuing relationship with NHS and government to explore how unnecessary bureaucracy can be eliminated from the healthcare system so that new treatments can reach patients as quickly as possible.”

The UK life sciences sector currently faces huge upheaval as the government pushes through the biggest set of reforms to the NHS in its 60-year history while also reforming the pricing and reimbursement system.

Nick Stephens, CEO of RSA, said: “These are challenging times for the UK life sciences industry as it copes with a host of issues including NHS reorganisation and new commercial arrangements.
“Moving forward, government urgently needs to do more to ensure that education, regulation, access to medicines and the NHS research base align to support the industry's continued contribution to the UK economy in this field.”

The 2010 UK Life Sciences Leaders Survey captured a general feeling of optimism as a new Conservative-led coalition government took office, but this year's survey reveals that to have been replaced by an even split between the quite optimistic, quite pessimistic, and the indifferent.

The general consensus from the survey seems to be that UK competitiveness has deteriorated and the government could be doing more to create the right environment for life sciences to prosper.

The 2011 survey also found:

• The cost of doing business in the UK has continued to rise and may be driving business offshore to emerging and lower cost markets. Key cost areas included: clinical trials, employment, materials, transport and manufacturing

NHS reforms are creating challenges for life science industry leaders, as are key issues such as the future medicines pricing systems and changing models of engagement

• The regulatory burden – from both the UK and EU - was cited as one of the top three issues for preclinical research and development, clinical research, and for medical departments in general.

On the specific question of value-based pricing, nearly half addressing the issue in the survey believed it will reduce market access and lead to the UK falling behind as an early launch market.

In contrast, health technology assessments – such as those provided by NICE - were broadly welcomed as a means of enhancing value and meeting therapeutic needs.

The survey was carried out during August 2011 and supported by the ABPI, BioIndustry Association (BIA), Association of British Healthcare Industries (ABHI), the British In Vitro Diagnostics Associations (BIVDA) and the Ethical Medicines Industry Group (EMIG).

9th November 2011


Featured jobs

Subscribe to our email news alerts


Add my company
Hayward Medical Communications

Hayward Medical Communications has been supporting partners in every sector of the healthcare industry to deliver evidence-based, clinically relevant and...

Latest intelligence

The Biosimilar Challenge
How health behaviours and clinical outcomes are related
When HCPs understand patient activation levels they can actively guide patients towards more confident self-management of diverse health concerns....
The Periodic Table of Healthcare Communications
The definitive framework for building healthcare communication strategies and plans. Covering Brand Planning, Customer Experience and Multi-channel Marketing....